Actuate Therapeutics Common Stock Market Outlook
| ACTU Stock | 4.33 0.09 2.12% |
Slightly above 62% of all Actuate Therapeutics' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Actuate Therapeutics Common suggests that some traders are interested. Actuate Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Actuate Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 62
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Actuate Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Actuate Therapeutics Common.
News SentimentBullish | Hype SentimentBullish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Actuate Therapeutics Common is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Actuate Therapeutics Common given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Actuate Therapeutics Common, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Actuate Therapeutics Advice
The Actuate recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Actuate Therapeutics Common. Macroaxis does not own or have any residual interests in Actuate Therapeutics Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Actuate Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
For the selected time horizon Actuate Therapeutics Common has a Mean Deviation of 3.23, Standard Deviation of 4.23 and Variance of 17.88We provide trade advice to complement the prevailing expert consensus on Actuate Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Actuate Therapeutics is not overpriced, please confirm all Actuate Therapeutics fundamentals, including its ebitda, earnings per share, as well as the relationship between the Earnings Per Share and working capital . Given that Actuate Therapeutics has a book value per share of (0.13) X, we suggest you to validate Actuate Therapeutics Common market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Actuate Therapeutics Trading Alerts and Improvement Suggestions
| Actuate Therapeutics generated a negative expected return over the last 90 days | |
| Actuate Therapeutics has high historical volatility and very poor performance | |
| Actuate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (27.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Actuate Therapeutics generates negative cash flow from operations | |
| Actuate Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 121874 shares by Daniel Schmitt of Actuate Therapeutics at 4.33 subject to Rule 16b-3 |
Actuate Therapeutics Returns Distribution Density
The distribution of Actuate Therapeutics' historical returns is an attempt to chart the uncertainty of Actuate Therapeutics' future price movements. The chart of the probability distribution of Actuate Therapeutics daily returns describes the distribution of returns around its average expected value. We use Actuate Therapeutics Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Actuate Therapeutics returns is essential to provide solid investment analysis for Actuate Therapeutics.
| Mean Return | -0.38 | Value At Risk | -8.67 | Potential Upside | 6.79 | Standard Deviation | 4.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Actuate Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Actuate Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Actuate Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Actuate Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Actuate stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.5 | |
β | Beta against Dow Jones | 1.81 | |
σ | Overall volatility | 4.23 | |
Ir | Information ratio | -0.11 |
Actuate Therapeutics Volatility Alert
Actuate Therapeutics Common exhibits very low volatility with skewness of 0.11 and kurtosis of 0.39. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Actuate Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Actuate Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Actuate Therapeutics Fundamentals Vs Peers
Comparing Actuate Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Actuate Therapeutics' direct or indirect competition across all of the common fundamentals between Actuate Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Actuate Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Actuate Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Actuate Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Actuate Therapeutics to competition |
| Fundamentals | Actuate Therapeutics | Peer Average |
| Return On Asset | -3.49 | -0.14 |
| Current Valuation | 107.19 M | 16.62 B |
| Shares Outstanding | 23.24 M | 571.82 M |
| Shares Owned By Insiders | 16.14 % | 10.09 % |
| Shares Owned By Institutions | 49.72 % | 39.21 % |
| Number Of Shares Shorted | 614.58 K | 4.71 M |
| Price To Book | 9.20 X | 9.51 X |
| EBITDA | (25.16 M) | 3.9 B |
| Net Income | (27.29 M) | 570.98 M |
| Total Debt | 404.99 K | 5.32 B |
| Book Value Per Share | (0.13) X | 1.93 K |
| Cash Flow From Operations | (21.84 M) | 971.22 M |
| Short Ratio | 7.32 X | 4.00 X |
| Earnings Per Share | (3.11) X | 3.12 X |
| Target Price | 26.75 | |
| Number Of Employees | 10 | 18.84 K |
| Market Capitalization | 136.67 M | 19.03 B |
| Total Asset | 9.32 M | 29.47 B |
| Retained Earnings | (132.38 M) | 9.33 B |
| Working Capital | 405.4 K | 1.48 B |
| Net Asset | 9.32 M |
Note: Disposition of 121874 shares by Daniel Schmitt of Actuate Therapeutics at 4.33 subject to Rule 16b-3 [view details]
Actuate Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Actuate . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Actuate Therapeutics Buy or Sell Advice
When is the right time to buy or sell Actuate Therapeutics Common? Buying financial instruments such as Actuate Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Actuate Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investor Favorites Thematic Idea Now
Investor Favorites
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.